7.9 C
New York
Thursday, April 18, 2024
HomeMarkets
Markets

Tesaro Doubles Off Ovarian Cancer Drug Trial Results

By Insider Scoop
0
8
psw-placeholder
psw-placeholder

Courtesy of Benzinga.

Tesaro Inc (NASDAQ: TSRO) shares are trading higher by $41.70 at $78.91 in Wednesday’s session. The catalyst for the torrid rally is the announcement that the Phase 3 Nova trial of Niraparib achieved its primary endpoint of progression-free survival.

Related Link: TESARO Spikes 110% After Drug Significantly Improved Progression-Free Survival For Ovarian Cancer Patients

The rally from the pre-market session has carried over big time into the regular session. Investors didn’t hesitate to go long the issue even after a $30+ higher open. In fact, it dipped only $0.28 to $68.50 before continuing its move higher. So far, it has reached $79.80 and is not far off that level.

Posted-In: Technicals Intraday Update Movers Trading Ideas

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,357FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

Load more

Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

Contact us: support@philstockworld.com

© Copyright - PSW, LLC.

2024
0
Would love your thoughts, please comment.x
()
x